

## Performance in Initiating Clinical Research – Q4 2016-17

REC Number	IRAS Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met	Comments	Reasons for delay correspond to:
14/LO/1206	154429	PLATFORM	17-Mar-16	25/01/2017	No	Study application submitted before the study were ready to submit due to the closure of CSP Module	Neither
13/SC/0154	112665	FAIT	24-Mar-16	19/07/2016	No	Study application submitted before the study were ready to submit due to the closure of CSP Module	Neither

## HRA Approval

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
16/EM/0193	190690	DALCOR	29/09/2016	18/03/2016	17/06/2016	14/06/2016	26/07/2016	12/08/2016	12/08/2016	No eligible patients were seen within the 70 day period	Neither

**Performance in Delivering Clinical Research – Q4 2016-17**

REC Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
15/EM/0344	183906	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatumimab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma (MORab)	Number Agreed	2	2	Date Agreed	31/10/2017	1	11/01/2017	Withdrawn By Sponsor